{"entity":{"id":"nct05057494","kind":"trial","name":"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","aka":[],"tldr":"A phase 3 trial of Acalabrutinib, Venetoclax and Obinutuzumab in chronic lymphocytic leukaemia, run by AstraZeneca, active and no longer recruiting.","summary":"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma is a phase 3 interventional study registered as NCT05057494 by AstraZeneca, with 607 participants enrolled, started 2022-09-12 and due to reach its primary completion in 2027-07-15. Interventions recorded: Acalabrutinib, Venetoclax and Obinutuzumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05057494","url":"https://clinicaltrials.gov/study/NCT05057494"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":["acalabrutinib","venetoclax","obinutuzumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05057494","phase":"3","setting":"A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","sponsor":"AstraZeneca","enrolled":607,"outcomes":[]},"route":"/trials/nct05057494/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"},{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}